Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218146 | 0.83 | RIPK1 (0.61) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL5305295 | 0.76 | NPC1 (0.70) | PRKACAMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1678647 | 0.76 | NOS3 (0.69) | ILKNOS3NOS1NOS2 | |
| SCHEMBL21588479 | 0.75 | SMN1; SMN2 (0.50) | MEN1ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL18384865 | 0.75 | RIPK1 (0.55) | MEN1ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL1678641 | 0.74 | NOS3 (0.48) | ILKPIK3CAPIK3CGHRH3NOS3 | |
| SCHEMBL5219432 | 0.74 | NPC1 (0.52) | ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL5215893 | 0.72 | NOS3 (0.60) | HRH3PRKACANOS3NOS1NOS2 | |
| SCHEMBL5183026 | 0.72 | HRH3 (0.72) | HRH3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7984841 | 0.72 | SMN1; SMN2 (0.56) | PIK3CAPIK3CGMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| EP-1539724-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014885-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | GAP43, NLN, TRPV1 | ILK 2264/4885PIK3CA 4127/4885PIK3CG 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.